JP6898306B2 - Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 - Google Patents
Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 Download PDFInfo
- Publication number
- JP6898306B2 JP6898306B2 JP2018507641A JP2018507641A JP6898306B2 JP 6898306 B2 JP6898306 B2 JP 6898306B2 JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018507641 A JP2018507641 A JP 2018507641A JP 6898306 B2 JP6898306 B2 JP 6898306B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- mmol
- lcms
- esi
- grams
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CCOC(CN1CCN(CC2N=CC(C(F)=Cc(c3c4)n[n](*)c3ccc4OC(C)c(c(Cl)cnc3)c3Cl)=CC2)CC1)=O Chemical compound CCOC(CN1CCN(CC2N=CC(C(F)=Cc(c3c4)n[n](*)c3ccc4OC(C)c(c(Cl)cnc3)c3Cl)=CC2)CC1)=O 0.000 description 13
- OZOQTENKIVKILK-UHFFFAOYSA-N Cc1cc(C#N)c(C)cc1 Chemical compound Cc1cc(C#N)c(C)cc1 OZOQTENKIVKILK-UHFFFAOYSA-N 0.000 description 2
- PXGGFGPWMIBEPC-UHFFFAOYSA-N Bc(cc1)ccc1C(O)=O Chemical compound Bc(cc1)ccc1C(O)=O PXGGFGPWMIBEPC-UHFFFAOYSA-N 0.000 description 1
- KLZFZVDNBXKIAO-MYKKPKGFSA-N C/C(/c(c(Cl)cnc1)c1Cl)=[O]\c1ccc2[nH]nc(/C=C(/c3ccc(CN4CCN(CC(O)=O)CC4)nc3)\F)c2c1 Chemical compound C/C(/c(c(Cl)cnc1)c1Cl)=[O]\c1ccc2[nH]nc(/C=C(/c3ccc(CN4CCN(CC(O)=O)CC4)nc3)\F)c2c1 KLZFZVDNBXKIAO-MYKKPKGFSA-N 0.000 description 1
- UNZKASIPWLTSJL-UHFFFAOYSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2-c(cc1)ccc1C(N1CCOCC1)=O Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2-c(cc1)ccc1C(N1CCOCC1)=O UNZKASIPWLTSJL-UHFFFAOYSA-N 0.000 description 1
- UGAZFBIQRLNRFQ-KSEXSDGBSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C(/c1ccc(CN2CCOCC2)nc1)\F Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C(/c1ccc(CN2CCOCC2)nc1)\F UGAZFBIQRLNRFQ-KSEXSDGBSA-N 0.000 description 1
- HCBJSRYFMQVIHO-DUXPYHPUSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c(cc(c(CN1CCOCC1)c1)N)c1F Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c(cc(c(CN1CCOCC1)c1)N)c1F HCBJSRYFMQVIHO-DUXPYHPUSA-N 0.000 description 1
- FMLOJWLGKYTNKP-CSKARUKUSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c1ccc(CN2CC(C)OC(C)C2)cc1 Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c1ccc(CN2CC(C)OC(C)C2)cc1 FMLOJWLGKYTNKP-CSKARUKUSA-N 0.000 description 1
- WEFLJLDGSYZDBL-ACCUITESSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c1ccc(CN2CCC(Cc3ccccc3)CC2)cc1 Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c1ccc(CN2CCC(Cc3ccccc3)CC2)cc1 WEFLJLDGSYZDBL-ACCUITESSA-N 0.000 description 1
- MBBJPSXIWFKOLG-VQHVLOKHSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c1ccc(CN2CCN(C)CC2)cc1 Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C/c1ccc(CN2CCN(C)CC2)cc1 MBBJPSXIWFKOLG-VQHVLOKHSA-N 0.000 description 1
- WBPNPGBCDBJEOY-LRTDYKAYSA-N CC(c(c(Cl)cnc1)c1Cl)Oc(cc12)ccc1[nH]nc2-c(cc1)ccc1C(N(CC1)C[C@@H]1N(C)C)=O Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc(cc12)ccc1[nH]nc2-c(cc1)ccc1C(N(CC1)C[C@@H]1N(C)C)=O WBPNPGBCDBJEOY-LRTDYKAYSA-N 0.000 description 1
- SVYNXEYNAVVIBC-PKNBQFBNSA-N CC(c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3ccc(CN4CCCCC4)cc3)c2c1 Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3ccc(CN4CCCCC4)cc3)c2c1 SVYNXEYNAVVIBC-PKNBQFBNSA-N 0.000 description 1
- ADTFWYRSZFADIC-VQHVLOKHSA-N CC(c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3ccc(CNC4CCN(C)CC4)cc3)c2c1 Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3ccc(CNC4CCN(C)CC4)cc3)c2c1 ADTFWYRSZFADIC-VQHVLOKHSA-N 0.000 description 1
- CBLWOPNESGMCDI-ACCUITESSA-N CC(c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3ccc(CNc4ccccc4)cc3)c2c1 Chemical compound CC(c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3ccc(CNc4ccccc4)cc3)c2c1 CBLWOPNESGMCDI-ACCUITESSA-N 0.000 description 1
- VYLIORWIFDJVCE-UHFFFAOYSA-N CC1(C)OB(c2ccc(C(OC)OC)nc2)OC1(C)C Chemical compound CC1(C)OB(c2ccc(C(OC)OC)nc2)OC1(C)C VYLIORWIFDJVCE-UHFFFAOYSA-N 0.000 description 1
- LPKITZIDHBWGFH-UHFFFAOYSA-N CC1=C[I]=CC=C1 Chemical compound CC1=C[I]=CC=C1 LPKITZIDHBWGFH-UHFFFAOYSA-N 0.000 description 1
- JNAOAOSJEVJEPO-FYWRMAATSA-N CCN(Cc1ccccc1)Cc1ccc(/C=C/c2n[nH]c(cc3)c2cc3OC(C)c(c(Cl)cnc2)c2Cl)cc1 Chemical compound CCN(Cc1ccccc1)Cc1ccc(/C=C/c2n[nH]c(cc3)c2cc3OC(C)c(c(Cl)cnc2)c2Cl)cc1 JNAOAOSJEVJEPO-FYWRMAATSA-N 0.000 description 1
- CYCZKCWLBJELDM-ZMFRSBBQSA-N CCOC(CN1CCN(CC(N=C2)=CCC2/C(/F)=C/c(c2c3)n[nH]c2ccc3OC(C)c(c(Cl)cnc2)c2Cl)CC1)=O Chemical compound CCOC(CN1CCN(CC(N=C2)=CCC2/C(/F)=C/c(c2c3)n[nH]c2ccc3OC(C)c(c(Cl)cnc2)c2Cl)CC1)=O CYCZKCWLBJELDM-ZMFRSBBQSA-N 0.000 description 1
- VVPFOGQWEDEBLX-UHFFFAOYSA-N CCOP(C(c1cnc(CN2CCOCC2)cc1)F)(O)=O Chemical compound CCOP(C(c1cnc(CN2CCOCC2)cc1)F)(O)=O VVPFOGQWEDEBLX-UHFFFAOYSA-N 0.000 description 1
- JGCACHOBCXQDAA-UHFFFAOYSA-N CCc(nc1)ccc1C(OC)=O Chemical compound CCc(nc1)ccc1C(OC)=O JGCACHOBCXQDAA-UHFFFAOYSA-N 0.000 description 1
- ZZGVXCUKGWMGOM-UHFFFAOYSA-N COC(c1ccc(C=O)cn1)OC Chemical compound COC(c1ccc(C=O)cn1)OC ZZGVXCUKGWMGOM-UHFFFAOYSA-N 0.000 description 1
- CSZUJAGXJWZEAZ-UHFFFAOYSA-N COC(c1cnc(CN2CCOCC2)cc1)=O Chemical compound COC(c1cnc(CN2CCOCC2)cc1)=O CSZUJAGXJWZEAZ-UHFFFAOYSA-N 0.000 description 1
- KCPDCYCCMCEYQN-BYPYZUCNSA-N C[C@@H](c(c(Cl)cnc1)c1Cl)O Chemical compound C[C@@H](c(c(Cl)cnc1)c1Cl)O KCPDCYCCMCEYQN-BYPYZUCNSA-N 0.000 description 1
- PZHSRIZSFVGFDC-KWCCSABGSA-N C[C@H](CNC(c(cc1)ccc1-c(c1c2)n[nH]c1ccc2OC(C)c(c(Cl)cnc1)c1Cl)=O)O Chemical compound C[C@H](CNC(c(cc1)ccc1-c(c1c2)n[nH]c1ccc2OC(C)c(c(Cl)cnc1)c1Cl)=O)O PZHSRIZSFVGFDC-KWCCSABGSA-N 0.000 description 1
- AJHZGVQJUVSPIX-LPXJLTLPSA-N C[C@H](c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C(/c1ccc(CN[C@H](C2)C[C@@H]2O)nc1)\F Chemical compound C[C@H](c(c(Cl)cnc1)c1Cl)Oc(cc1)cc2c1[nH]nc2/C=C(/c1ccc(CN[C@H](C2)C[C@@H]2O)nc1)\F AJHZGVQJUVSPIX-LPXJLTLPSA-N 0.000 description 1
- GLEHFSDTTRBCCU-SUQGKYDKSA-N C[C@H](c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3cccc(CNC4CCOCC4)c3)c2c1 Chemical compound C[C@H](c(c(Cl)cnc1)c1Cl)Oc1ccc2[nH]nc(/C=C/c3cccc(CNC4CCOCC4)c3)c2c1 GLEHFSDTTRBCCU-SUQGKYDKSA-N 0.000 description 1
- UUHVIQZMMNEZQH-UHFFFAOYSA-N Cc(cc(c(C)c1)F)c1C#N Chemical compound Cc(cc(c(C)c1)F)c1C#N UUHVIQZMMNEZQH-UHFFFAOYSA-N 0.000 description 1
- VYPPZXZHYDSBSJ-UHFFFAOYSA-N Cc(nc1)ccc1C(OC)=O Chemical compound Cc(nc1)ccc1C(OC)=O VYPPZXZHYDSBSJ-UHFFFAOYSA-N 0.000 description 1
- KZNRNQGTVRTDPN-UHFFFAOYSA-N Cc1cc(Cl)c(C)cc1 Chemical compound Cc1cc(Cl)c(C)cc1 KZNRNQGTVRTDPN-UHFFFAOYSA-N 0.000 description 1
- HBXFIXSFKULBOG-UHFFFAOYSA-N Cc1cc(F)c(C)c(F)c1 Chemical compound Cc1cc(F)c(C)c(F)c1 HBXFIXSFKULBOG-UHFFFAOYSA-N 0.000 description 1
- YFSLBELJYPLIHB-UHFFFAOYSA-N Cc1cc(F)c(C)cc1N Chemical compound Cc1cc(F)c(C)cc1N YFSLBELJYPLIHB-UHFFFAOYSA-N 0.000 description 1
- RIKQFBGCNQAHBO-UHFFFAOYSA-N Cc1ccc(C)c(C(F)(F)F)c1 Chemical compound Cc1ccc(C)c(C(F)(F)F)c1 RIKQFBGCNQAHBO-UHFFFAOYSA-N 0.000 description 1
- APQSQLNWAIULLK-UHFFFAOYSA-N Cc1ccc(C)c2c1cccc2 Chemical compound Cc1ccc(C)c2c1cccc2 APQSQLNWAIULLK-UHFFFAOYSA-N 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N Cc1ccc(C)cc1 Chemical compound Cc1ccc(C)cc1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- BGVTUIRPHLSMJU-UHFFFAOYSA-N Cc1nnc(C)cc1 Chemical compound Cc1nnc(C)cc1 BGVTUIRPHLSMJU-UHFFFAOYSA-N 0.000 description 1
- ITKTWKRBXCOJDE-UHFFFAOYSA-N Clc1ncc(CBr)cn1 Chemical compound Clc1ncc(CBr)cn1 ITKTWKRBXCOJDE-UHFFFAOYSA-N 0.000 description 1
- HJVDYBUDQLXLKH-UHFFFAOYSA-N Ic(cn1)cnc1I Chemical compound Ic(cn1)cnc1I HJVDYBUDQLXLKH-UHFFFAOYSA-N 0.000 description 1
- MMKAQOLNUBDHRF-UHFFFAOYSA-N Ic(cn1)ncc1I Chemical compound Ic(cn1)ncc1I MMKAQOLNUBDHRF-UHFFFAOYSA-N 0.000 description 1
- LOLZZYHVCHHARH-UHFFFAOYSA-N N#Cc(cc(CBr)cc1)c1Br Chemical compound N#Cc(cc(CBr)cc1)c1Br LOLZZYHVCHHARH-UHFFFAOYSA-N 0.000 description 1
- CIFSHVKGUBPAPN-UHFFFAOYSA-N N#Cc(cc(CN1CCOCC1)cc1)c1Br Chemical compound N#Cc(cc(CN1CCOCC1)cc1)c1Br CIFSHVKGUBPAPN-UHFFFAOYSA-N 0.000 description 1
- LKAVTWPQAPQMLM-UHFFFAOYSA-N O=Cc1ccc(CN2CCOCC2)nc1 Chemical compound O=Cc1ccc(CN2CCOCC2)nc1 LKAVTWPQAPQMLM-UHFFFAOYSA-N 0.000 description 1
- DDKUCAPHWJDXNQ-UHFFFAOYSA-N OCc1cnc(CN2CCOCC2)cc1 Chemical compound OCc1cnc(CN2CCOCC2)cc1 DDKUCAPHWJDXNQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510484124.6 | 2015-08-07 | ||
| CN201510484124 | 2015-08-07 | ||
| CN201510908082 | 2015-12-09 | ||
| CN201510908082.4 | 2015-12-09 | ||
| PCT/CN2016/092989 WO2017024968A1 (zh) | 2015-08-07 | 2016-08-03 | 作为fgfr和vegfr抑制剂的乙烯基化合物 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2018531218A JP2018531218A (ja) | 2018-10-25 |
| JP2018531218A6 JP2018531218A6 (ja) | 2018-12-13 |
| JP2018531218A5 JP2018531218A5 (enExample) | 2019-09-19 |
| JP6898306B2 true JP6898306B2 (ja) | 2021-07-07 |
Family
ID=57983012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018507641A Active JP6898306B2 (ja) | 2015-08-07 | 2016-08-03 | Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10519133B2 (enExample) |
| EP (1) | EP3333157B1 (enExample) |
| JP (1) | JP6898306B2 (enExample) |
| CN (1) | CN107922349B (enExample) |
| WO (1) | WO2017024968A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018151126A1 (ja) * | 2017-02-14 | 2018-08-23 | 富士フイルム株式会社 | インダゾール化合物の製造方法およびインダゾール化合物 |
| US11078194B2 (en) | 2017-12-07 | 2021-08-03 | Harbin Zhenbao Pharmaceutical Co., Ltd. | Salt form and crystal form serving as FGFR and VEGFR inhibitor compounds, and preparation method therefor |
| CN113490667B (zh) * | 2018-12-29 | 2023-10-27 | 盛世泰科生物医药技术(苏州)股份有限公司 | 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物 |
| WO2020156564A1 (zh) | 2019-02-02 | 2020-08-06 | 南京明德新药研发有限公司 | 作为pd-l1免疫调节剂的乙烯基吡啶甲酰胺基化合物 |
| AU2020214518B2 (en) * | 2019-02-02 | 2022-12-15 | Novaonco Js Therapeutics Co., Ltd. | Fluorovinylbenzamide compound as PD-L1 immunomodulator |
| WO2020249096A1 (zh) * | 2019-06-14 | 2020-12-17 | 南京明德新药研发有限公司 | 作为fgfr和vegfr双重抑制剂的并环类化合物 |
| WO2021088859A1 (zh) * | 2019-11-06 | 2021-05-14 | 暨南大学 | 吲唑类化合物及其药用组合物和应用 |
| US12441707B2 (en) | 2019-12-30 | 2025-10-14 | Tyra Biosciences, Inc. | Indazole compounds |
| EP4186894B1 (en) * | 2020-08-11 | 2024-12-04 | Henan Medinno Pharmaceutical Technology Co., Ltd. | Fgfr inhibitor compound and use thereof |
| MX2023007162A (es) * | 2020-12-17 | 2023-06-29 | Blossomhill Therapeutics Inc | Macrociclos y sus usos. |
| CN116761798A (zh) * | 2020-12-30 | 2023-09-15 | 泰拉生物科学公司 | 作为激酶抑制剂的吲唑类化合物 |
| PE20240687A1 (es) | 2020-12-30 | 2024-04-10 | Tyra Biosciences Inc | Compuestos de indazol como inhibidores de cinasas |
| US20240316022A1 (en) * | 2021-06-30 | 2024-09-26 | Tyra Biosciences, Inc. | Indazole compounds |
| JP2025525433A (ja) * | 2022-06-29 | 2025-08-05 | タイラ・バイオサイエンシーズ・インコーポレイテッド | インダゾール化合物 |
| CN116239623B (zh) * | 2022-11-18 | 2025-11-18 | 江西亚太科技发展有限公司 | 一种硼酸酯的制备方法及其应用 |
| WO2024137742A1 (en) | 2022-12-20 | 2024-06-27 | Blueprint Medicines Corporation | Compounds and compositions as fgfr3 degraders and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020010137A1 (en) * | 1997-09-18 | 2002-01-24 | Genentech, Inc. | Methods and compositions for inhibiting neoplastic cell growth |
| YU54202A (sh) * | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| NZ524717A (en) | 2000-09-11 | 2004-09-24 | Chiron Corp | Quinolinone derivatives |
| JP2004536113A (ja) * | 2001-07-03 | 2004-12-02 | カイロン コーポレイション | チロシンキナーゼおよびセリン／スレオニンキナーゼのインヒビターとしてのインダゾールベンズイミダゾール化合物 |
| US7429609B2 (en) | 2002-05-31 | 2008-09-30 | Eisai R & D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
| US20060058366A1 (en) * | 2002-12-03 | 2006-03-16 | Kyowa Hakko Kogyo Co., Ltd. | Jnk inhibitor |
| DK1585743T3 (da) * | 2002-12-19 | 2007-09-17 | Pfizer | 2-(H-indazol-6-ylamino)-benzamid forbindelser som protein kinase inhibitorer, nyttige til behandling opthalmiske sygdomme |
| WO2007058626A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Indazole compounds |
| US8008481B2 (en) * | 2006-03-31 | 2011-08-30 | Ericsson Anna M | Indazole compounds |
| JO2860B1 (en) * | 2009-05-07 | 2015-03-15 | ايلي ليلي اند كومباني | Phenylendazolyl compounds |
-
2016
- 2016-08-03 JP JP2018507641A patent/JP6898306B2/ja active Active
- 2016-08-03 WO PCT/CN2016/092989 patent/WO2017024968A1/zh not_active Ceased
- 2016-08-03 EP EP16834592.4A patent/EP3333157B1/en active Active
- 2016-08-03 CN CN201680046188.0A patent/CN107922349B/zh active Active
- 2016-08-03 US US15/750,704 patent/US10519133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018531218A (ja) | 2018-10-25 |
| EP3333157A4 (en) | 2018-10-17 |
| EP3333157B1 (en) | 2020-12-23 |
| US10519133B2 (en) | 2019-12-31 |
| US20180222886A1 (en) | 2018-08-09 |
| CN107922349A (zh) | 2018-04-17 |
| CN107922349B (zh) | 2021-05-07 |
| EP3333157A1 (en) | 2018-06-13 |
| WO2017024968A1 (zh) | 2017-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6898306B2 (ja) | Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 | |
| JP2018531218A6 (ja) | Ｆｇｆｒ及びｖｅｇｆｒ阻害剤であるビニル化合物 | |
| JP7377798B2 (ja) | ｃ－ＭＥＴ／ＡＸＬ阻害剤としてのウラシル系化合物 | |
| US10654808B2 (en) | Tyrosine kinase inhibitor and pharmaceutical composition comprising same | |
| JP7233410B2 (ja) | Ｅｇｆｒキナーゼ阻害薬としてのアリールホスフィンオキシド | |
| JP6600365B2 (ja) | Ｊａｋ阻害剤 | |
| TWI819470B (zh) | Fgfr激酶抑制劑及其應用 | |
| KR20190110103A (ko) | Ask1 억제제로서의 피리딘 유도체 및 이의 제조방법과 용도 | |
| JP2016537369A (ja) | カゼインキナーゼ１ｄ／ｅ阻害剤としての置換された４，５，６，７−テトラヒドロピラゾロ［１，５−ａ］ピラジン誘導体 | |
| JP2017519821A (ja) | ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミドン類似体 | |
| JP7050054B2 (ja) | Ｐｄｅ４阻害剤としての縮合環系化合物 | |
| CN109311908B (zh) | 作为Akt抑制剂的二氢吡唑氮杂卓类化合物 | |
| CN107614501B (zh) | 羟基嘌呤类化合物及其应用 | |
| JP7063899B2 (ja) | Ｆｇｆｒ４阻害剤、その製造方法及び使用 | |
| HK40004140A (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40004140B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40018495B (en) | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor | |
| HK40018495A (en) | Aryl-phosphorus-oxygen compound as egfr kinase inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190723 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190806 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20200610 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200610 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200630 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200728 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201028 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210312 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210518 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210610 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6898306 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |